Literature DB >> 8356967

Epidemiologic analysis of Kaposi's sarcoma as an early and later AIDS outcome in homosexual men.

D R Hoover1, C Black, L P Jacobson, O Martínez-Maza, D Seminara, A Saah, J Von Roenn, R Anderson, H K Armenian.   

Abstract

The authors separately studied the epidemiology (risk and risk factors) of Kaposi's sarcoma occurring as an initial acquired immunodeficiency syndrome (AIDS) outcome (early Kaposi's sarcoma) and later after a different initial AIDS outcome (later Kaposi's sarcoma) in a cohort of 2,591 human immunodeficiency virus type 1-infected gay men of the Multicenter AIDS Cohort Study between 1984 and 1992. Among 844 AIDS cases, 202 presented with early Kaposi's sarcoma, 101 subsequently developed later Kaposi's sarcoma, and 541 were not diagnosed with Kaposi's sarcoma. Overall, 37.4% of AIDS cases were diagnosed with Kaposi's sarcoma prior to death. Kaposi's sarcoma diagnosed on the skin was significantly more common with early Kaposi's sarcoma (77.3%) than with later Kaposi's sarcoma (65.1%). Men presenting with an AIDS outcome other than Kaposi's sarcoma were at high risk for later Kaposi's sarcoma. Later Kaposi's sarcoma onset in men with a previous AIDS outcome was associated with the following characteristics: 1) lower immune status prior to AIDS and 2) longer post-AIDS survival. A Kaposi's sarcoma diagnosis in a man with a previous AIDS illness approximately doubled the risk (hazard) for death. Histories of urethral gonorrhea and scabies prior to study entry were more common in early Kaposi's sarcoma cases than in later Kaposi's sarcoma cases. However, self-reported sexual activity at study entry and prior to AIDS onset was highest in the later Kaposi's sarcoma group. In this cohort, cigarette smoking had a protective association against all Kaposi's sarcoma in univariate and multivariate models. Only 21.0% of the later Kaposi's sarcoma and 25.0% of the early Kaposi's sarcoma men smoked at least one-half pack of cigarettes daily at study entry compared with 33.8% of non-Kaposi's sarcoma and 35.5% of seroprevalent men still AIDS free. The reasons for this surprising association are unclear. However, other evidence which documents that habitual smoking alters the immune system (and possibly cytokine levels) in ways that could perhaps influence Kaposi's sarcoma pathogenesis should be considered.

Entities:  

Mesh:

Year:  1993        PMID: 8356967     DOI: 10.1093/oxfordjournals.aje.a116855

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  13 in total

Review 1.  Frequency of policy recommendations in epidemiologic publications.

Authors:  L W Jackson; N L Lee; J M Samet
Journal:  Am J Public Health       Date:  1999-08       Impact factor: 9.308

Review 2.  Impact of antiretroviral therapy on the incidence of Kaposi's sarcoma in resource-rich and resource-limited settings.

Authors:  Aggrey S Semeere; Naftali Busakhala; Jeffrey N Martin
Journal:  Curr Opin Oncol       Date:  2012-09       Impact factor: 3.645

3.  Cancer burden attributable to cigarette smoking among HIV-infected people in North America.

Authors:  Sean F Altekruse; Meredith S Shiels; Sharada P Modur; Stephanie R Land; Kristina A Crothers; Mari M Kitahata; Jennifer E Thorne; William C Mathews; Diana M Fernández-Santos; Angel M Mayor; John M Gill; Michael A Horberg; John T Brooks; Richard D Moore; Michael J Silverberg; Keri N Althoff; Eric A Engels
Journal:  AIDS       Date:  2018-02-20       Impact factor: 4.177

4.  Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men.

Authors:  C M Lyles; N M Graham; J Astemborski; D Vlahov; J B Margolick; A J Saah; H Farzadegan
Journal:  Eur J Epidemiol       Date:  1999-02       Impact factor: 8.082

5.  Sexual activity and Kaposi's sarcoma among human immunodeficiency virus type 1 and human herpesvirus type 8-coinfected men.

Authors:  Eric W Nawar; Stephen R Cole; Homayoon Farzadegan; Mallory D Witt; Frank J Jenkins; Joseph B Margolick; John P Phair; Lisa P Jacobson
Journal:  Ann Epidemiol       Date:  2008-05-27       Impact factor: 3.797

6.  Risk factors for classical Kaposi sarcoma in a population-based case-control study in Sicily.

Authors:  Lesley A Anderson; Carmela Lauria; Nino Romano; Elizabeth E Brown; Denise Whitby; Barry I Graubard; Yan Li; Angelo Messina; Lorenzo Gafà; Francesco Vitale; James J Goedert
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-12       Impact factor: 4.254

7.  Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma.

Authors:  Richard F Little; Karen Aleman; Pallavi Kumar; Kathleen M Wyvill; James M Pluda; Elizabeth Read-Connole; Victoria Wang; Stefania Pittaluga; Andrew T Catanzaro; Seth M Steinberg; Robert Yarchoan
Journal:  Blood       Date:  2007-09-10       Impact factor: 22.113

8.  11. Cancers attributable to infection in the UK in 2010.

Authors:  D M Parkin
Journal:  Br J Cancer       Date:  2011-12-06       Impact factor: 7.640

9.  Trends in Kaposi's Sarcoma in Miami Beach from 1987 to 2007.

Authors:  Simon B Zeichner; Ana L Ruiz; Gabriel P Suciu; Rachel Lerner Zeichner; Estelamari Rodriguez
Journal:  ISRN Oncol       Date:  2012-12-25

10.  The interaction between smoking status and highly active antiretroviral therapy (HAART) use on the risk of Kaposi's sarcoma (KS) in a cohort of HIV-infected men.

Authors:  H N Luu; E S Amirian; M E Scheurer
Journal:  Br J Cancer       Date:  2013-02-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.